Vigel Home What is Vigel? Enhancer Features Vigel Clinical Trials Vigel FAQ Vigel News Vigel for Men? Other Resources                 VIGEL Clinical Trials VIGEL was studied extensively in two clinical trials. One study was conducted on post-menopausal women who were affected by Female Sexual Arousal Disorder (FSAD) for at least six months. This study was designed to determine the effects of L-Arginine (one of Vigel's main ingredients) on vaginal blood flow and sexual arousal as well as physiological responses to erotic stimuli. It demonstrated that the mechanism responsible for the increase in sexual arousal was the body's enhanced production of Nitric Oxide due to the administration of L-Arginine. The results of another clinical study showed a significant improvement in the Subjects' level of desire and overall sexual satisfaction. This double-blind, placebo-controlled study included 93 women (aged 22-73) who enrolled as participants who were lacking sexual desire. 46 of these women received L-Arginine, while the other 47 received a placebo. The participants then used a "Female Sexual Function Index Questionnaire" to rate their level of sexual health before starting the study, and after taking either a placebo or the L-Arginine. After only four weeks, 62% of the active L-Arginine group reported significantly improved satisfaction with their overall sex life, and 64% reported an improvement in their level of sexual desire.     © 2008